Capital Guardian Trust Co. boosted its stake in Biogen by 130.1% in the fourth quarter. Inc. now owns 385 shares of the biotechnology company's stock valued at $104,000 after purchasing an additional 50 shares during the period.
There has been some selling insider activity on Biogen Inc. (NASDAQ:BIIB) was up +1.16% during the last trading session, with a day high of 332.87.
Short traders are feeling a little more bearish on shares of Biogen Inc. recently as evidenced by the uptick in short interest. It has underperformed by 11.76% the S&P500.
Livforsakringsbolaget Skandia Omsesidigt increased Aetna Inc (AET) stake by 14.02% reported in 2017Q2 SEC filing. The shares were purchased at an average price of $290.01. The value in dollars went from $750,000 to $907,000 a change of $157,000 since the last quarter. The stock increased 0.20% or $0.05 during the last trading session, reaching $25.35.
About 14,009 shares traded. General Mills, Inc. (NYSE:GIS) has declined 10.63% since October 11, 2016 and is downtrending. It has underperformed by 18.62% the S&P500.
Investors sentiment increased to 1.31 in 2017 Q2. Its down 0.16, from 1.04 in 2017Q1. 25 funds opened positions while 77 raised stakes. Cowen & Co maintained the shares of OIS in report on Friday, July 7 with "Hold" rating. Grantham Mayo Van Otterloo Limited Com accumulated 24,484 shares or 0.04% of the stock. Jnba invested 0.01% of its portfolio in Loews Corporation (NYSE:L). Parallax Volatility Advisers Ltd Partnership holds 16,592 shares. State Board Of Administration Of Florida Retirement Sys holds 0% of its portfolio in Oil States International, Inc. Tph Asset Management Llc owns 603,786 shares or 1.73% of their U.S. portfolio. Artisan Prtn Limited Partnership stated it has 2.04M shares or 0.18% of all its holdings. Aperio Grp Limited Com holds 0.16% or 95,761 shares. North Star Investment Mgmt Corp, a Illinois-based fund reported 21,612 shares. Moreover, Perritt Capital Management Inc has 0.6% invested in the company for 141,121 shares. (NYSE:OIS) for 520,358 shares. The Virginia-based Outfitter Advisors Ltd. has invested 0.49% in the stock. As of the last earnings report the EPS was $15.24 and is expected to be $21.54 for the current year with 211,432,000 shares now outstanding. BIIB's profit will be $1.19 billion for 14.66 P/E if the $5.61 EPS becomes a reality. The biotechnology company reported $5.04 EPS for the quarter, topping the consensus estimate of $4.36 by $0.68.
Motco, which manages about $959.43 million US Long portfolio, decreased its stake in Nestle Sa (NSRGY) by 52,317 shares to 40,701 shares, valued at $3.55 million in 2017Q2, according to the filing. Reduces Holdings in Biogen Inc. Winfield Associates Inc. grew its holdings in shares of Biogen by 16.8% in the first quarter. (NASDAQ:BIIB), 15 have Buy rating, 0 Sell and 11 Hold. Therefore 58% are positive. They now have a Dollars 375 price target on the stock. Biogen Idec Inc. had 68 analyst reports since July 23, 2015 according to SRatingsIntel. Eleven research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company's stock. Piper Jaffray upgraded Biogen Inc (NASDAQ:BIIB) on Thursday, November 5 to "Overweight" rating. They issued a "sector perform" rating and a $319.00 price target on the stock. The rating was maintained by Argus Research with "Buy" on Monday, July 27. On Wednesday, July 26 the stock rating was maintained by H.C. Wainwright with "Buy".
07/26/2017 - Biogen Idec Inc. had its "buy" rating reiterated by analysts at Deutsche Bank. On Wednesday, June 7 the stock rating was maintained by Jefferies with "Hold". The company was downgraded on Thursday, March 16 by Morgan Stanley. Finally, BMO Capital Markets upped their price objective on shares of Biogen from $328.00 to $377.00 and gave the company a "market perform" rating in a report on Wednesday, September 13th.
07/10/2017 - Jefferies began new coverage on Biogen Idec Inc. giving the company a "hold" rating.
Investors sentiment decreased to 0.88 in 2017 Q2. Its up 0.39, from 0.99 in 2017Q1. It turned negative, as 81 investors sold BIIB shares while 321 reduced holdings. 93 funds opened positions while 344 raised stakes. 25,814 were accumulated by Norinchukin Comml Bank The. Eads & Heald Invest Counsel reported 1,016 shares. Baldwin Brothers Incorporated Ma invested 0.02% of its portfolio in Biogen Inc (NASDAQ:BIIB). Meridian Management invested in 1.32% or 9,251 shares. Amica Mutual Insur reported 11,334 shares. (NASDAQ:BIIB), 15 have Buy rating, 0 Sell and 11 Hold. Wetherby Asset Mgmt invested in 3,035 shares. Carroll Financial Associates Inc. raised its position in Biogen by 1.2% in the second quarter. 3,106 are held by Trust Comm Of Vermont. Davis R M invested in 930 shares or 0.01% of the stock. (NYSE:OIS). Arizona State Retirement Systems reported 0.01% stake. Loring Wolcott And Coolidge Fiduciary Advsrs Llp Ma accumulated 8,512 shares. Eqis Capital Mngmt has invested 0.06% in Biogen Inc (NASDAQ:BIIB). The Company also has a collaboration agreement with Genentech, Inc. Biogen Inc now has $70.37B valuation. The Firm focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. It has a 24.03 P/E ratio. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Since May 1, 2017, it had 1 buying transaction, and 1 sale for $102,593 activity. Guardian Life Insurance Co. of America now owns 839 shares of the biotechnology company's stock worth $229,000 after acquiring an additional 6 shares in the last quarter.